Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Zhonghua Nei Ke Za Zhi ; 62(11): 1311-1316, 2023 Nov 01.
Artigo em Chinês | MEDLINE | ID: mdl-37935497

RESUMO

Objective: To explore the effectiveness and safety of endovascular treatment (EVT) for patients with acute anterior circulation ischemic stroke with symptom onset exceeding 24 h. Methods: In this retrospective cohort study, data were extracted from patients who underwent endovascular treatment for acute anterior circulation ischemic stroke at the First Hospital of Jilin University from February 2019 to April 2022. A total of 569 patients were included, with a mean age of 63 (54-70) years. Among them, 398 (69.9%) were male. The patients were divided into two groups based on symptom onset time:>24 h group and≤24 h group. Propensity score matching (PSM) was used to match the patients in a 1︰1 ratio between the>24 h group and the≤24 h group. Logistic regression was used to evaluate the impact of symptom onset time on outcome events. Results: Before PSM, compared with≤24 h group, the>24 h group had a younger age [56 (48, 64) vs. 64 (55, 70), Z=-3. 60, P<0.001]; lower proportion of prior atrial fibrillation [1.8% (1/57) vs. 21.1% (108/512), χ2=12.39, P<0.001]; lower proportion of wake-up stroke [7.0% (4/57) vs. 27.7% (142/512), χ2=11.54, P<0.001]; lower baseline NIHSS score [11.0 (7.5, 14.0) vs. 13.0 (10.0, 16.0), Z=-3.22, P<0.001]; and a higher American Society of Interventional and Therapeutic Neuroradiology/Society of Interventional Radiology(ASITN/SIR) grading (P<0.001). After PSM, there were no significant differences in baseline characteristics between the two groups. There was no significant difference in the proportion of patients with a modified Rankin Scale (mRS) score≤2 at 90 days after surgery between the two groups (before matching: 42.0% vs. 40.4%, OR=0.745, 95%CI 0.407-1.362, P=0.339; after matching: 51.8% vs. 39.3%, OR=0.511, 95%CI 0.212-1.236, P=0.136). No significant differences were observed in the incidence of any safety outcomes between the>24 h group and the≤24 h group. Conclusion: For patients with acute anterior circulation ischemic stroke with symptom onset exceeding 24 h, EVT is feasible after strict radiological screening and has similar safety and effectiveness as for patients with symptom onset under 24 h.


Assuntos
Isquemia Encefálica , Procedimentos Endovasculares , AVC Isquêmico , Acidente Vascular Cerebral , Humanos , Masculino , Pessoa de Meia-Idade , Feminino , Acidente Vascular Cerebral/terapia , Acidente Vascular Cerebral/etiologia , AVC Isquêmico/terapia , Isquemia Encefálica/terapia , Estudos Retrospectivos , Resultado do Tratamento
2.
Zhonghua Jie He He Hu Xi Za Zhi ; 41(4): 296-300, 2018 Apr 12.
Artigo em Chinês | MEDLINE | ID: mdl-29690686

RESUMO

Objective: To investigate the respiratory central hypoxia response and its related factors in Han and Uygur patients with obstructive sleep apnea hypopnea syndrome (OSAHS). Methods: One hundred and sixty six OSAHS patients were selected from Jan. 2016 to Dec. 2016 in Department of Respiratory and Critical Care Medicine, Kelamayi Central Hospital, including 69 cases of Han nationality and 97 cases of Uygur nationality. Seventy-three healthy subjects of Uygur nationality were enrolled as the control group. All of them under went sleep monitoring, nocturnal oxygen saturation (SaO(2)), pulmonary function and respiratory central hypoxia response. Results: The 3 groups were matched for age, gender, body mass index(BMI) and apnea-hypopnea index(AHI). The Uygur patients had a higher oxygen desaturation index (ODI4) [(30±22) per hour vs (18±17) per hour ] than Han patients of the same age and BMI. Compared to Han patients, Uygur patients had weaker hypoxic responsiveness [(-0.41±0.23) L·min(-1)·%(-1) vs (-0.36±0.22) L·min(-1)·%(-1,) P<0.05], and the difference still existed after adjusting for AHI [(-0.31±0.21) L·min(-1)·%(-1) vs (-0.41±0.22) L·min(-1)·%(-1,) P<0.05] in mild OSAHS, but this difference was not significant in severe OSAHS. Conclusions: The central hypoxic response in Uygur OSAHS patients was lower than that in Han OSAHS patients and normal controls.


Assuntos
Gasometria , Hipóxia , Oxigênio/uso terapêutico , Apneia Obstrutiva do Sono/fisiopatologia , Estudos de Casos e Controles , Humanos , Sono/fisiologia , Síndrome
3.
Eur Rev Med Pharmacol Sci ; 21(7): 1509-1513, 2017 04.
Artigo em Inglês | MEDLINE | ID: mdl-28429356

RESUMO

OBJECTIVE: The aim of this study was to evaluate the safety and efficacy of intra-arterial thrombolysis (IAT) using urokinase (UK) in acute stroke patients without angiographically-documented occlusion, and to define predictors of clinical outcome. PATIENTS AND METHODS: We analyzed clinical and radiological data of acute ischemic stroke patients whose angiography did not show an arterial occlusion within six hours of symptom onset and who were further treated with IAT using UK. The primary outcome was a modified Rankin Scale (mRS) score ≤ 2 at 90 days' post procedure. RESULTS: In a thrombolysis database of 263 patients, we identified 51 patients without angiographically-documented arterial occlusion who received IAT with UK within six hours of symptom onset. The median baseline NIH stroke scale measurement was 11 (range: 8-20). From symptom onset, the mean time to treatment was 4.1 ± 1.3 h (median: 4.5 h; range: 1.5-6.0 h). Immediate and dramatically clinical improvement was seen in 29/51 (56.9%) patients. One patient (2.0%) developed a symptomatic intracranial hemorrhage. At three months, 38/51 (74.5%) patients were independent (mRS ≤2), 13/51 (25.5%) patients were dependent (mRS > 3), and no patients died. No predictors of clinical outcome were identified. CONCLUSIONS: IAT using UK can be a safe and efficacious therapy for the treatment of acute ischemic stroke in patients without angiographic occlusion. Approximately 75% of these patients had a favorable clinical outcome and thrombolysis-related symptomatic hemorrhage was low.


Assuntos
Fibrinolíticos/administração & dosagem , Acidente Vascular Cerebral/tratamento farmacológico , Terapia Trombolítica , Isquemia Encefálica/tratamento farmacológico , Humanos , Resultado do Tratamento , Ativador de Plasminogênio Tipo Uroquinase
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...